MX2018007272A - Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales. - Google Patents
Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales.Info
- Publication number
- MX2018007272A MX2018007272A MX2018007272A MX2018007272A MX2018007272A MX 2018007272 A MX2018007272 A MX 2018007272A MX 2018007272 A MX2018007272 A MX 2018007272A MX 2018007272 A MX2018007272 A MX 2018007272A MX 2018007272 A MX2018007272 A MX 2018007272A
- Authority
- MX
- Mexico
- Prior art keywords
- naftazone
- pharmaceutical composition
- salts
- pulsatile release
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende naftazona o una de sus sales farmacéuticamente aceptable, para usarse para la liberación pulsátil de naftazona o una de sus sales farmacéuticamente aceptable, en donde: - un primer pulso de naftazona o una de sus sales farmacéuticamente aceptable es liberado sustancialmente inmediatamente después de la administración oral de tal composición farmacéutica, y - al menos un pulso adicional de naftazona o una de sus sales farmacéuticamente aceptable es liberado a aproximadamente 3 horas hasta aproximadamente 8 horas después de tal administración oral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307026 | 2015-12-16 | ||
| PCT/EP2016/081007 WO2017102846A1 (en) | 2015-12-16 | 2016-12-14 | Pulsatile release pharmaceutical composition comprising naftazone or one of its salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018007272A true MX2018007272A (es) | 2019-01-10 |
Family
ID=55024039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007272A MX2018007272A (es) | 2015-12-16 | 2016-12-14 | Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190000784A1 (es) |
| EP (1) | EP3389642A1 (es) |
| JP (1) | JP2019504116A (es) |
| CN (1) | CN108697660A (es) |
| AU (1) | AU2016374382A1 (es) |
| BR (1) | BR112018012214A2 (es) |
| CA (1) | CA3008197A1 (es) |
| HK (1) | HK1257509A1 (es) |
| MX (1) | MX2018007272A (es) |
| WO (1) | WO2017102846A1 (es) |
| ZA (1) | ZA201804036B (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1054019A1 (en) | 1999-05-18 | 2000-11-22 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose |
| FR2796552A1 (fr) | 1999-07-21 | 2001-01-26 | Centre Nat Rech Scient | Nouvelle utilisation de derives de la beta-naphtoquinone et de leurs sels pour la fabrication de medicaments exercant un effet inhibiteur sur la liberation de glutamate dans le cerveau |
| US6680069B1 (en) | 1999-11-09 | 2004-01-20 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose and process for manufacturing the same |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
-
2016
- 2016-12-14 EP EP16820207.5A patent/EP3389642A1/en not_active Withdrawn
- 2016-12-14 AU AU2016374382A patent/AU2016374382A1/en not_active Abandoned
- 2016-12-14 WO PCT/EP2016/081007 patent/WO2017102846A1/en active Application Filing
- 2016-12-14 CA CA3008197A patent/CA3008197A1/en not_active Abandoned
- 2016-12-14 MX MX2018007272A patent/MX2018007272A/es unknown
- 2016-12-14 US US16/062,358 patent/US20190000784A1/en not_active Abandoned
- 2016-12-14 JP JP2018550866A patent/JP2019504116A/ja active Pending
- 2016-12-14 CN CN201680074159.5A patent/CN108697660A/zh active Pending
- 2016-12-14 BR BR112018012214A patent/BR112018012214A2/pt not_active Application Discontinuation
-
2018
- 2018-06-15 ZA ZA2018/04036A patent/ZA201804036B/en unknown
- 2018-12-19 HK HK18116314.5A patent/HK1257509A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3008197A1 (en) | 2017-06-22 |
| ZA201804036B (en) | 2019-02-27 |
| JP2019504116A (ja) | 2019-02-14 |
| WO2017102846A1 (en) | 2017-06-22 |
| US20190000784A1 (en) | 2019-01-03 |
| AU2016374382A1 (en) | 2018-07-05 |
| BR112018012214A2 (pt) | 2018-11-27 |
| EP3389642A1 (en) | 2018-10-24 |
| HK1257509A1 (zh) | 2019-10-25 |
| CN108697660A (zh) | 2018-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007915A (es) | Compuestos de benzopirazol y analogos de estos. | |
| NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
| SV2018005682A (es) | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana | |
| EP4349406A3 (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
| AU2018231044A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| BR112017028140A2 (pt) | formulações farmacêuticas | |
| PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| UY36124A (es) | Derivados de carboxamida | |
| WO2015125152A3 (en) | Pharmaceutical compositions of asenapine | |
| TR201721505A2 (tr) | Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| MX2018008153A (es) | Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene. | |
| WO2016020408A3 (en) | Compounds for preventing ototoxicity | |
| WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
| MX2018007272A (es) | Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales. | |
| MX2017014301A (es) | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. | |
| PH12016502527A1 (en) | Stabilized desmopressin | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| PH12018502490A1 (en) | Oral tipepidine preparation |